CRISPR Therapeutics CRSP Issuance Costs Associated With The Notes In Accounts Payable And Accrued Expenses
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept crsp:IssuanceCostsAssociatedWithTheNotesInAccountsPayableAndAccruedExpenses.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's issuance costs associated with the notes in accounts payable and accrued expenses.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's issuance costs associated with the notes in accounts payable and accrued expenses?
- CRISPR Therapeutics (CRSP) reported issuance costs associated with the notes in accounts payable and accrued expenses of $1.12M in Q1 2026.